"metastatic cancer" trang 7 - tải miễn phí từ tailieuXANH
The SystHERs registry: An observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer

The SystHERs registry: An observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer
11    69    0
The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer

The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer
12    68    0
Ceramide targets xIAP and cIAP1 to sensitize metastatic colon and breast cancer cells to apoptosis induction to suppress tumor progression

Ceramide targets xIAP and cIAP1 to sensitize metastatic colon and breast cancer cells to apoptosis induction to suppress tumor progression
17    57    0
Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry

Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry
7    69    0
Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: Final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)

Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: Final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)
8    65    0
Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: Final results from phase II AIO KRK 0105 trial

Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: Final results from phase II AIO KRK 0105 trial
7    45    0
Cytostasis and morphological changes induced by mifepristone in human metastatic cancer cells involve cytoskeletal filamentous actin reorganization and impairment of cell adhesion dynamics

Cytostasis and morphological changes induced by mifepristone in human metastatic cancer cells involve cytoskeletal filamentous actin reorganization and impairment of cell adhesion dynamics
15    64    0
The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer

The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer
11    57    0
Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: A comparison of different schedules and treatments

Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: A comparison of different schedules and treatments
10    63    0
High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer

High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer
10    51    0
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: Efficacy in combination with hormonal therapy

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: Efficacy in combination with hormonal therapy
7    58    0
Toward developing a metastatic breast cancer treatment strategy that incorporates history of response to previous treatments

Toward developing a metastatic breast cancer treatment strategy that incorporates history of response to previous treatments
12    40    1
Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600- mutated metastatic colorectal cancer: A real-world study in Spain

Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600- mutated metastatic colorectal cancer: A real-world study in Spain
10    34    1
Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: A meta-analysis

Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: A meta-analysis
11    40    1
The EPICURE study: A pilot prospective cohort study of heterogeneous and massive data integration in metastatic breast cancer patients

The EPICURE study: A pilot prospective cohort study of heterogeneous and massive data integration in metastatic breast cancer patients
9    36    1
REMARRY and PURSUIT trials: Liquid biopsyguided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer

REMARRY and PURSUIT trials: Liquid biopsyguided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer
6    226    1
MONARCC: A randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as firstline therapy for RAS and BRAF wildtype metastatic colorectal cancer: A study by the Australasian Gastrointestinal Trials Group (AGITG)

MONARCC: A randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as firstline therapy for RAS and BRAF wildtype metastatic colorectal cancer: A study by the Australasian Gastrointestinal Trials Group (AGITG)
9    82    1
Labeling efficiency of Tb3+ conjugated CD133 monoclonal antibody nanocomplex targeting in vitro metastatic cancer cells

Labeling efficiency of Tb3+ conjugated CD133 monoclonal antibody nanocomplex targeting in vitro metastatic cancer cells
6    226    1
Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
9    78    1
Phase II trial of nab-paclitaxel in metastatic breast cancer patients with visceral metastases

Phase II trial of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
8    56    1
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.